For Discovery & Sharing: Visit Vox World

For Support: +1 608-716-7539

Voximetry Announces $5M Pre-A Financing to Advance Dosimetry Imaging Biomarker

Proceeds to support advancement of extremely accurate and precise biomarker  for improved management of theranostic treatments. MADISON, Wis.—Voximetry is an early commercial stage medical software and services company with unique technology to enable personalized Radiopharmaceutical Therapy (RPT) treatments for prostate and other cancer patients. The round was company led, with participation from Wisconsin Alumni Research Foundation […]

Voximetry Accelerates AI Technology Development with Strategic Technology Transfer Agreement

Voximetry, Inc and Theravision, AB aim to speed the deployment of AI-based training models in Radiopharmaceutical Therapy (RPT) dosimetry to reach patients faster. MADISON, Wis.— Voximetry is a commercial stage medical software and services company with proprietary advanced dosimetry technology and an experienced team dedicated to supporting the clinical use and development of personalized Radiopharmaceutical […]

Voximetry Accelerates Global Footprint with Key Regulatory Leadership New Hire

MADISON, Wis.– Voximetry Incorporated, a Healthtech company with software designed to change the Standard of Care for late-stage prostate cancer patients by creating personalized treatment plans tailored for the individual, has announced the appointment of Jill Kaeder as Vice President of Regulatory Affairs and Quality Assurance. Jill has worked in Medical Device regulated environments for […]

Voximetry Awarded $4 Million Grant from National Cancer Institute to Automate Advanced Radiopharmaceutical Therapy Dosimetry Software

MADISON, Wis.—Voximetry is a commercial stage medical software and services company with advanced technology to enable personalized Radiopharmaceutical Therapy (RPT) treatments for prostate and other cancer patients.   The company has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary software for […]

Voximetry Launches Clinical Operations Support to accelerate adoption of Torch® Dose Assessment and Dosimetry Services

MADISON, Wis.– Voximetry Inc., a Healthtech company with software designed to change the Standard of Care for late-stage prostate cancer patients by creating personalized treatment plans tailored for the individual, has announced the appointment of Patrick Morse, MBA, as Vice President of Global Clinical Operations. Patrick has over 12 years of leadership experience in industry […]

Voximetry positions for growth with hiring of Chief Operating Officer Dr. Abhi Chakrabarti

MADISON, Wis.– Voximetry Inc., a Healthtech company with software designed to change the Standard of Care for late-stage prostate cancer patients by creating personalized treatment plans tailored for the individual, has announced the appointment of Dr. Abhimanyu Chakrabarti as Chief Operating Officer. Dr. Chakrabarti has over 25 years of global development and commercial leadership experience […]

Pluvicto Demonstrates Clinical Benefit in Prostate Cancer Before Chemo

Pluvicto becomes the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients BEFORE receiving taxane-based chemotherapy, addressing a significant unmet need Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM , a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint.  This study is the first PSMA-targeted radioligand therapy to demonstrate […]

Voximetry Exhibits at SNMICON 2022 New Delhi, India

Voximetry is very pleased to participate in the 54th Annual Conference of the Society of Nuclear Medicine (India), SNMICON 2022, from December 8th -12th. We invite you to visit us during the exhibition at the booth of BJ. Madan & Co. and learn how Torch®, the accuracy leader and only full Monte Carlo GPU-accelerated voxel-based […]

Voximetry Receives FDA Clearance For Torch

MADISION, WI – Voximetry is very pleased to announce FDA 510(k) market clearance for Torch® Dose Assessment for Radiopharmaceutical Therapy (RPT), the first commercial full Monte Carlo GPU-accelerated voxel-based dosimetry solution.   Torch can provide estimates of absorbed radiation dose following internal administration of approved radiopharmaceuticals, Torch can provide estimates of absorbed radiation dose in seconds.  […]